؉ lymphocytes and causes adult T-cell leukemia/lymphoma (ATLL), an aggressive lymphoproliferative disease that is often fatal. Here, we demonstrate that the HTLV-1 pX splice-variant p30 II markedly enhances the transforming potential of Myc and transcriptionally activates the human cyclin D2 promoter, dependent upon its conserved Myc-responsive E-box enhancer elements, which are associated with increased S-phase entry and multinucleation. Enhancement of c-Myc transforming activity by HTLV-1 p30 II is dependent upon the transcriptional coactivators, transforming transcriptional activator protein/p434 and TIP60, and it requires TIP60 histone acetyltransferase (HAT) activity and correlates with the stabilization of HTLV-1 p30 II /Myc-TIP60 chromatin-remodeling complexes. The p30 II oncoprotein colocalizes and coimmunoprecipitates with Myc-TIP60 complexes in cultured HTLV-1-infected ATLL patient lymphocytes. Amino acid residues 99 to 154 within HTLV-1 p30 II interact with the TIP60 HAT, and p30 II transcriptionally activates numerous cellular genes in a TIP60-dependent or TIP60-independent manner, as determined by microarray gene expression analyses. Importantly, these results suggest that p30 II functions as a novel retroviral modulator of Myc-TIP60-transforming interactions that may contribute to adult T-cell leukemogenesis.
The human T-cell lymphotropic virus type 1 (HTLV-1) infects and transforms CD4
؉ lymphocytes and causes adult T-cell leukemia/lymphoma (ATLL), an aggressive lymphoproliferative disease that is often fatal. Here, we demonstrate that the HTLV-1 pX splice-variant p30 II markedly enhances the transforming potential of Myc and transcriptionally activates the human cyclin D2 promoter, dependent upon its conserved Myc-responsive E-box enhancer elements, which are associated with increased S-phase entry and multinucleation. Enhancement of c-Myc transforming activity by HTLV-1 p30 II is dependent upon the transcriptional coactivators, transforming transcriptional activator protein/p434 and TIP60, and it requires TIP60 histone acetyltransferase (HAT) activity and correlates with the stabilization of HTLV-1 p30 II /Myc-TIP60 chromatin-remodeling complexes. The p30 II oncoprotein colocalizes and coimmunoprecipitates with Myc-TIP60 complexes in cultured HTLV-1-infected ATLL patient lymphocytes. Amino acid residues 99 to 154 within HTLV-1 p30 II interact with the TIP60 HAT, and p30 II transcriptionally activates numerous cellular genes in a TIP60-dependent or TIP60-independent manner, as determined by microarray gene expression analyses. Importantly, these results suggest that p30 II functions as a novel retroviral modulator of Myc-TIP60-transforming interactions that may contribute to adult T-cell leukemogenesis.
The human T-cell lymphotropic virus type-1 (HTLV-1) infects CD4
ϩ T cells and causes adult T-cell leukemia/lymphoma (ATLL), an aggressive lymphoproliferative disease that is often fatal (59, 61, 65, 83) . HTLV-1-infected leukemic lymphocytes exhibit deregulated cell cycle progression and characteristic multinucleation or polyploidy (evidenced by the appearance of flower-shaped or lobulated nuclei). A conserved sequence, known as pX, located within the 3Ј terminus of the HTLV-1 genome, encodes at least five nonstructural regulatory factors, including the viral transactivator Tax and an alternative splice-variant, p30 II (or Tax open reading frame II
[ORF II], Tof), which was shown to possess a functional transactivation domain (6, 13, 15, 29, 34, 35, 66, 86, 87) . The pX sequence is generally retained in the majority of ATLL patient isolates, even those containing partially deleted proviruses (33, 68) , indicative of its importance for pathogenesis. The viral Tax protein transcriptionally activates numerous lymphoproliferative pathways (NF-B, CREB/ATF, and p67 SRF ) (29, 72, 73, 74, 75, 80, 84, 88) and has been shown to inhibit transcription functions associated with the tumor suppressor p53, which likely contributes to a loss of G 1 /S-phase checkpoint control in HTLV-1-infected T cells (8, 46, 58) . Many of the pleiotropic effects of Tax upon cellular signaling may derive from its aberrant recruitment of the transcriptional coactivators, p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor (P/CAF) (9, 22, 23, 27, 36, 37, 49, 50, 77, 78) . Further, Tax interacts with cell cycle modulators, including D-type cylin-cdk4/6 complexes, retinoblastoma (Rb) protein, and the human mitotic arrest deficiency type 1 (hMAD-1) protein (21, 28, 31, 32, 39, 47, 52, 76) . Although HTLV-1 Tax expression markedly promotes G 1 /S transition (38, 40, 64) , Tax has been demonstrated to inhibit Myc-dependent transactivation and prevent Myc-associated anchorageindependent cell growth (67) . As ATLL patient-derived lymphocytes and tumors from HTLV-1 pX transgenic mice are known to possess deregulated Myc functions, these findings collectively suggest that other pX-encoded factors may influence Myc to promote cellular transformation by HTLV-1 (20, 43, 63) .
The Myc transcription factor promotes S-phase cell cycle entry, induces apoptosis or programmed cell death, and causes neoplastic cellular transformation (2, 3, 7, 12, 19, 41, 51) . The expression of the Myc protooncogene is deregulated in many solid tumors and hematological malignancies, including ATLL, diffuse large-cell lymphomas, CD30
ϩ anaplastic large-cell lymphomas, and Burkitt's B-cell lymphomas (18, 24, 26, 43, 55, 60) . The transforming viruses, HTLV-1 and Epstein Barr virus, deregulate Myc functions associated with development of ATLL and Burkitt's lymphomas, respectively (11, 18, 26, 43, 63, 67) . Our preliminary studies indicated that the HTLV-1 accessory protein p30
II markedly increases S-phase cell cycle progression and induces significant polyploidy. As relatively little is known with respect to the roles of pX-encoded factors (e.g., p30
II , p13 II , p12 I , and Rex p27 ) in HTLV-1-associated pathogenesis (6, 29, 34, 35) , we sought to characterize the molecular mechanism by which p30
II promotes Myc-dependent S-phase progression and multinucleation. While others have proposed that p30 II 's transcriptional functions are targeted against the viral LTR to repress HTLV-1 gene expression (1, 86, 87) , the physiological role of p30 II in ATLL-development remains unclear. Using microarray analyses, we now demonstrate that numerous cellular genes are transcriptionally activated by HTLV-1 p30 II in a 60-kDa Tat-interacting protein (TIP60)-dependent or TIP60-independent manner. Nicot et al. (48) and Younis et al. (85) have shown that p30 II binds and inhibits nuclear export of the doubly spliced Tax/Rex HTLV-1 mRNA, and it is intriguing that p30 II might perform diverse functions to regulate viral gene expression and promote altered cellular growth, as has been noted for Tax, which drives LTR transactivation and deregulates host lymphoproliferativesignaling pathways (13, 21, 28, 29, 38, 40, 47, 52, 64, (72) (73) (74) (75) (76) 84 II mutant exhibited an approximately 20 to 50% reduction in transformation efficiency compared to the wild-type ACH.wt (62) , suggesting that p30 II is required for the full transforming potential of HTLV-1. Importantly, our findings indicate that HTLV-1 p30
II is a novel retroviral modulator of Myc transcriptional and of transforming activities that may significantly contribute to adult T-cell leukemogenesis through stabilization of Myc-TIP60 transcriptional interactions.
MATERIALS AND METHODS
Plasmids, transfections, and cell culture. HeLa cells (ATCC CCL-2) were grown in Dulbecco's modified Eagle's medium (DMEM; ATCC) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals), 100 U/ml penicillin, and 100 g/ml streptomycin sulfate (Invitrogen-Life Technologies) and cultured at 37°C and 5% CO 2 . 293A fibroblasts (Quantum Biotechnology) were cultured in ATCC 46-X medium supplemented with sodium bicarbonate (Invitrogen-Life Technologies), 10% FBS, and 100 U/ml penicillin and 100 g/ml streptomycin sulfate. Molt-4 (ATCC CRL-1582), Jurkat E6.1 (ATCC TIB-152) and HTLV-1-infected MJ[G11] (ATCC CRL-8294) and HuT-102 lymphocytes (ATCC TIB-162) were grown in RPMI medium (ATCC) supplemented with 20% FBS, 100 U/ml penicillin, 100 g/ml streptomycin sulfate, and 20 g/ml gentamicin sulfate (Sigma Chemical Corp.) and cultured at 10% CO 2 . Primary HTLV-1-infected lymphocytes were obtained after informed consent from three ATLL patients (ATL-1, ATL-2, ATL-3) and were cultured in RPMI medium supplemented with 20% FBS, 50 U/ml hIL-2 (Invitrogen-Life Technologies), 100 U/ml penicillin, 100 g/ml streptomycin sulfate, and 20 g/ml gentamicin sulfate. The cytomegalovirus (CMV)-HTLV-1 p30 II (hemagglutinin [HA]) expression construct was kindly provided by G. Franchini (NCI, NIH) and has been reported by Koralnik et al. (34) . pSG5-HTLV-1 p13 II (10) , which expresses a protein corresponding to amino acid residues 155 to 241 of HTLV-1 p30 II , was provided by V. Ciminale (University of Padua, Italy) and CMV-HTLV-1 p13 II (HA) was provided by C. Nicot (University of Kansas). In order to generate the human cyclin D2 promoter-luciferase reporter construct, sequences encompassing the human cyclin D2 promoter were located in the clone with GenBank accession number U47284; according to these sequences, a PCR product that contains 1,622 nucleotides upstream of the ATG start codon was generated. Two closely spaced E-boxes (5Ј-CACGTG) are localized within the promoter region which binds Myc/Max/ Mad network components (7). This fragment was cloned into the pGL3-luciferase vector. Both E-box sequences were mutated to 5Ј-CTCGAG using the quick change method. The M4-tk-luciferase (M4-tk-luc) reporter plasmid was reported by Bouchard et al. (7) and Vervoorts et al. (79) . The C␤F-FLAG-Myc, C␤F-FLAG-TRRAP 1261-1579 , C␤S-TRRAP antisense , and C␤S constructs were described by McMahon et al. (41) . The pOZ-wildtype-TIP60 and pOZ-TIP60 ⌬HAT expression constructs were reported by Ikura et al. (25) , and the CMV-TIP60 L497A expression plasmid was reported by Gaughan et al. (17) . All transfections were performed using Lipofectamine (Invitrogen-Life Technologies) or Superfect (QIAGEN) reagents as recommended by the manufacturers.
Cell cycle and fluorescence-activated cell sorter (FACS) analyses. Molt4 and Jurkat E6.1 lymphocytes were seeded in 100 mm 2 tissue culture dishes and transfected with CMV-HTLV-1 p30 II (HA) or an empty C␤S vector. After 48 h, cultures were split and either labeled for 4 h by adding BrdU (BD-Pharmingen) to the medium or immediately stained using annexin V-(fluorescein isothiocyanate [FITC])/propidium iodide (BD-Pharmingen). For cell cycle analyses, transfected BrdU-labeled cells were permeabilized and stained with a FITC-conjugated anti-BrdU antibody, and total genomic DNA was stained using 7-AAD (BD-Pharmingen). Flow cytometry was performed and data were analyzed using ModFit LT 3.0 software.
Focus formation/transformation assays. Immortalized Werner's Syndrome (WRN Ϫ/Ϫ ) fibroblasts (45) were seeded at 6 ϫ 10 5 cells in 60 mm 2 tissue-culture dishes in DMEM supplemented with 10% FBS and cultured at 37°C under 5% CO 2 . Cells were transfected with an empty C␤S vector, CMV-HTLV-1 p30 II (HA), C␤F-FLAG-Myc, and combinations of CMV-HTLV-1 p30 II (HA)/C␤F-FLAG-Myc or C␤S/C␤F-FLAG-Myc using Superfect reagent. Foci were observed within 2 weeks and quantified by direct counting. Expression of HTLV-1 p30 II (HA) was detected by fixing plates with 0.2% glutaraldehyde-1% formaldehyde in PBS and immunostaining using a monoclonal antibody against the HA epitope tag (CA5; Roche Molecular Biochemicals), diluted 1:1,000 in BLOTTO buffer (50 2 tissue-culture dishes for 10 min. Cells were pelleted by centrifugation and resuspended in 200 l SDS lysis buffer. Chromatin DNA was fragmented by sonication, and oligonucleosomal-protein complexes were immunoprecipitated using primary antibodies and 60 l salmon sperm DNA/protein A agarose. Precipitated oligonucleosomal-protein complexes were washed, cross-links were reversed, and bound DNA fragments were amplified by PCR using specific oligonucleotide primer pairs that flank conserved E-box elements within the human cyclin D2 gene promoter (PRM, 5Ј-C CCCTTCCTCCTGGAGTGAAATAC-3Ј and 5Ј-CGTGCTCTAACGCATCCT TGAGTC-3Ј) or anneal within an untranslated region (UTR, 5Ј-ATCAGACC CTATTCTCGGCTCAGG-3Ј and 5Ј-CAGTCAGTAAGGCACTTTATTTCCC C-3Ј), as described by Vervoorts et al. (79) . PCR products were electrophoresed through a 2% Tris-acetate-EDTA agarose gel and visualized by ethidium bromide staining.
RESULTS

HTLV-1 p30
II increases S-phase progression and promotes polyploidy. The conserved pX domain of HTLV-1 encodes at least five nonstructural regulatory factors, including the viral transactivator Tax and an alternative splice variant, p30 II (Fig.  1A) . The HTLV-1 p30
II protein is comprised of 241 amino acid residues and contains Arg-and Ser/Thr-rich domains (1, 34, 35) . RasMol structural prediction analyses (Brookhaven protein databank) indicate that p30 II possesses 4 alpha-helices and 19 beta-sheet regions (Fig. 1B) . The alpha-helices likely serve as interacting or docking sites for cellular factors, whereas the Ser/Thr-rich domains may provide targets for phosphorylation by kinases that modulate p30 II 's functions or interactions. As relatively little is known with respect to the functions of HTLV-1 pX accessory factors, such as p30 II , we investigated whether the p30 II protein contributes to lymphoproliferation in HTLV-1-infected T cells by altering cell cycle regulation. To determine whether HTLV-1 p30 II influences cell cycle progression and/or apoptosis, Molt-4 and Jurkat E6.1 lymphocytes were transfected with a CMV-HTLV-1 p30 II (HA) expression construct or an empty C␤S vector control, and transfected cultures were assayed for bromodeoxyuridine (BrdU)-incorporation/cell cycle progression or programmed cell death using flow cytometric analyses (Fig. 1C and D and data not shown).
II -expressing cells exhibit markedly increased Sphase progression and significant polyploidy as determined by BrdU incorporation and 7-AAD staining of total genomic DNA ( Fig. 1C and D , top left panels). However, p30
II did not induce apoptosis in transfected cells, as determined by annexin V-FITC/propidium iodide-staining and FACS ( Fig. 1C and D , top right panels). These results suggest that p30 II may contribute to lymphoproliferation and genomic instability in HTLV-1-infected cells during ATLL by affecting S-phase regulatory factors, such as Myc and/or E2F (2, 29, 43) .
The HTLV-1 p30 II protein interacts in Myc-TIP60 immune complexes in ATLL patient lymphocytes. The p30 II protein was detected in cultured HTLV-1-infected lymphocytes, derived from three different ATLL patients (ATL-1, ATL-2, ATL-3) diagnosed with clinical acute-stage leukemias, by immunofluorescence laser confocal microscopy and immunoblotting ( Fig. 2A and B) . Three-dimensional Z-stack composite images for ATL-3 demonstrate that p30 II /Myc proteins colocalize in the nucleus in all focal planes in HTLV-1-infected cells ( Fig. 2A, right panels) . Relative fluorescence intensities for p30 II /Myc-specific signals and DAPI (4Ј,6Ј-diamidino-2-phenylindole) nuclear staining are shown for reference ( Fig.  2A, right panels) . HTLV-1 p30
II is present in Myc-containing immunoprecipitated complexes in ATLL patient lymphocytes (Fig. 2B) . Intriguingly, immunoprecipitation of Myc revealed that TIP49 (RUVBL1), TIP48 (RUVBL2) (81) , and Max are present and are bound to Myc, but the TIP60 histone acetyltransferase (HAT) was not detected in Myc-containing coimmune complexes in uninfected Jurkat E6.1 lymphocytes (Fig.  2B) . The II (HA) coimmunoprecipitates with Myc, TRRAP, TIP60, and TIP49 (RUVBL1). However, TIP48 (RUVBL2) and RNA polymerase II were not detected in anti-HA immunoprecipitates, although both proteins were detected in control immunoprecipitations using antibodies against known interacting proteins (Fig. 2C ). To further confirm these interactions, we reimmunoprecipitated HTLV-1 p30 II (HA) from extracts prepared from transfected Jurkat T cells using antibodies against Myc, TRRAP, TIP60, TIP48, and TIP49 ( Fig. 2C , lower panels). A nonspecific antibody (rabbit preimmune serum) was included as a negative control. Interestingly, the ATPase/helicase, TIP48, was detected in p30 IIcomplexes immunoprecipitated with an anti-TIP48 (RUVBL2) polyclonal antibody (Fig. 2C , lower panels) (81) . These data suggest that HTLV-1 p30 II may modulate Myc functions through interactions with Myc-associated transcriptional coactivators on promoters of responsive genes (14) .
HTLV-1 p30 II transactivates Myc-responsive E-box elements within the human cyclin D2 promoter. To investigate the possibility that HTLV-1 p30
II might affect Myc-dependent transcription, we next cotransfected HeLa cells with a human cyclin D2 promoter-luciferase reporter construct, containing two conserved Myc-responsive E-box enhancer elements (CACGTG), in the presence of increasing amounts of CMV-HTLV-1 p30 II (HA). Results in Fig. 3A demonstrate that HTLV-1 p30 II significantly transactivates the human cyclin D2 promoter. A mutant cyclin D2 promoter, lacking Myc-responsive E-box elements (79), was not transcriptionally activated by p30 II , indicating that p30 II -mediated transactivation from the human cyclin D2 promoter requires the conserved Mycresponsive E-box enhancer elements ( Fig. 3A and B) . The HTLV-1 p30 II (HA)-tagged protein was detected in trans-fected cells by immunoblotting using a monoclonal anti-HA antibody (CA5; Roche Molecular Biochemicals) (Fig. 3A) . Intracellular levels of Myc were not altered by HTLV-1 p30 II expression (Fig. 3A , lower panels). HTLV-1 p30 II also transcriptionally activates the human cyclin D2 promoter in transfected 293A fibroblasts in a dose-dependent manner (Fig. 3C ). To confirm that HTLV-1 p30
II promotes Mycdependent transcription from E-box enhancer elements, we cotransfected 293A fibroblasts and HeLa cells with a synthetic tk minimal promoter-luciferase reporter construct (M4-tk-luc) that contains four tandem E-boxes (79) . As shown in Fig. 3D , HTLV-1 p30
II transactivates E-box enhancer elements within M4-tk-luc, suggesting that p30 II promotes S-phase progression through Myc-dependent transcriptional interactions. Interestingly, we observed that p30 II , at the lowest concentration used, induced approximately 13-fold transactivation from the synthetic M4-tk-luc promoter, whereas higher concentrations induced lower (5-to 7-fold) levels of transcriptional activation (Fig. 3D ). These observations are consistent with findings by Zhang et (56) . Myc has also previously been demonstrated to interact in chromatin-remodeling complexes with the ATMrelated TRRAP/p434 protein (41, 42, 51 ). Therefore, we tested whether HTLV-1 p30 II -mediated transactivation requires TIP60 and TRRAP/p434 functions. HeLa cells were cotrans-
FIG. 2. HTLV-1 p30
II interacts with Myc-TIP60 complexes in cultured ATLL patient-derived lymphocytes. (A) Immunofluorescence laser confocal microscopy was performed on HTLV-1-infected ATLL patient-derived T cells (ATL-1, ATL-2, and ATL-3) or Jurkat E6.1 lymphocytes as a negative control, using a rabbit polyclonal anti-HTLV-1 p30 II antibody (34) and a monoclonal anti-Myc antibody (Upstate Biotechnology). HTLV-1 p30
II was detected using a FITC-conjugated anti-rabbit secondary antibody (green), and Myc was detected using a Cy5-conjugated anti-mouse secondary antibody (blue; Jackson ImmunoResearch Laboratories). A three-dimensional Z-stack composite for ATL-3 is shown on the right. II (HA) expression is also shown. RNA polymerase II and TIP48 were immunoprecipitated from Jurkat E6.1 whole-cell extracts using antibodies against known binding partners (anti-p300 and anti-Myc). An anti-HTLV-1 Tax monoclonal antibody (22) was used as a negative control. The HTLV-1 p30 II (HA) protein was reimmunoprecipitated from extracts prepared from Jurkat E6.1 lymphocytes and transfected with either a C␤S vector control or CMV-HTLV-1 p30 II (HA), using antibodies against Myc, TIP60, TIP48, TIP49, or nonspecific rabbit preimmune serum (Control). Input levels for actin are shown for comparison. IP, coimmunoprecipitation. fected with a human cyclin D2 promoter-luciferase reporter construct and CMV-HTLV-1 p30 II (HA) in the presence of increasing amounts of CMV-TIP60, CMV-TIP60 ⌬HAT (a trans-dominant-negative HAT-inactive mutant [25] ), or CMV-TIP60 L497A , a COOH-terminal mutant impaired for interactions with cellular factors, including the androgen receptor (17) . Ectopic expression of TIP60 alone did not significantly transactivate the human cyclin D2 promoter; however, TIP60 overexpression enhanced HTLV-1 p30 II -mediated transactivation in a dose-dependent manner (Fig. 4A) . The trans-dominant-negative TIP60 ⌬HAT mutant potently inhibited p30 II -mediated transcriptional activation (Fig. 4A) , suggesting that
FIG. 3. HTLV-1 p30
II transcriptionally activates Myc-responsive elements within the human cyclin D2 promoter. (A) HeLa cells were cotransfected with a human cyclin D2 promoter-luciferase reporter plasmid (0.5 g) (7) and increasing amounts of CMV-HTLV-1 p30 II (HA) (0.008, 0.017, 0.035, 0.07, and 0.15 g). Cells were lysed by freeze-thawing, and luciferase assays were carried out using equivalent levels of total cellular proteins. The expression of HTLV-1 p30 II (HA), Myc, and actin in transfected cells is shown. (B) HeLa cells were cotransfected as described for panel A, with a mutant cyclin D2 promoter-luciferase construct lacking conserved Myc-responsive E-box enhancer elements (0.5 g) (7) and increasing amounts of CMV-HTLV-1 p30 II (HA). (C) 293A fibroblasts were cotransfected as described for panel A, with a human cyclin D2 promoter-luciferase reporter plasmid and increasing amounts of CMV-HTLV-1 p30 II (HA) (0.07, 0.15, 0.25, 0.5, 1.0 g); luciferase assays were performed as described above, using equivalent levels of total cellular proteins. HTLV-1 p30 II (HA), Myc, and actin proteins were detected by immunoblotting (lower panels). (D) 293A fibroblasts were cotransfected as described for panel A with a synthetic, E-box-containing minimal tk promoter-luciferase reporter construct (M4-tk-luc; 0.5 g) (79) HTLV-1 p30 II transactivation requires TIP60-associated HAT activity (25) . The TIP60 L497A mutant also weakly enhanced p30 II -mediated transactivation (Fig. 4A) . Overexpression of wild-type TIP60 or the trans-dominant-negative TIP60 ⌬HAT mutant did not alter expression of the HTLV-1 p30 II (HA) protein in transfected HeLa cells (Fig. 4A, lower panels) . Inhibition of TRRAP/p434, as a result of coexpressing either TRRAP antisense RNA or a trans-dominant-negative TRRAP mutant, TRRAP 1261-1579 (FLAG-epitope-tagged [41] ), prevented HTLV-1 p30 II -mediated transcriptional activation from the human cyclin D2 promoter (Fig. 4B) . The trans-dominantnegative, FLAG-tagged TRRAP 1261-1579 protein did not alter (25) relative to endogenous TIP60 was visualized by immunofluorescence microscopy using a rabbit polyclonal anti-TIP60 antibody (top panels) and an anti-FLAG M2 monoclonal antibody (bottom panels). The C␤S empty vector was transfected as a negative control. (D) To confirm the specificity of transcriptional inhibition by TRRAP antisense RNA, 293A fibroblasts were cotransfected with human cyclin D2 promoter-luciferase and CMV-HTLV-1 p30 II (HA) plasmids in the presence of either increasing amounts (0.5 and 1.0 g) of C␤S-TRRAP antisense (41) or of pSPORT-lacZ, which expresses ␤-galactosidase mRNA. Relative luciferase activities were determined from duplicate assays using approximately equivalent levels of total cellular proteins. (Fig. 4B, lower panels) . We then performed immunofluorescence microscopy, using a monoclonal anti-FLAG M2 antibody (Sigma Chemical Corp.) and a rabbit polyclonal anti-TIP60 antibody (Upstate Biotechnology), to visualize expression of the FLAG-tagged wild-type TIP60 or TIP60 ⌬HAT proteins relative to endogenous TIP60 (25) . Results shown in Fig. 4C demonstrate that the FLAGtagged TIP60 proteins were drastically overexpressed relative to endogenous TIP60 in transfected cells. To demonstrate the specificity of transcriptional inhibition due to TRRAP antisense RNA in panel B, we repeated these experiments using a pSPORT-lacZ control plasmid which expresses ␤-galactosidase mRNA. Results shown in Fig. 4D demonstrate that increased ␤-galactosidase mRNA expression did not influence HTLV-1 p30
II -dependent transactivation from the cyclin D2 promoter, whereas TRRAP antisense inhibited p30
II transcriptional activation in a dose-dependent manner. These data collectively indicate that HTLV-1 p30
II synergizes with the TIP60 HAT to transactivate Myc-responsive E-box elements within the human cyclin D2 promoter, requiring the transcriptional coactivator TRRAP/p434 (7, 25, 41, 79) .
HTLV-1 p30 II stabilizes Myc/TIP60 chromatin-remodeling transcription complexes in HTLV-1-infected lymphocytes. As we have shown that HTLV-1 p30
II transcriptionally activates the conserved Myc-responsive E-box enhancer elements within the human cyclin D2 promoter (Fig. 3A and C) (7) , we sought to determine whether p30 II is present in Myc-containing chromatin-remodeling complexes using the ChIP procedure as described by Vervoorts et al. (79) . Formaldehyde cross-linked genomic DNA complexes in uninfected Molt-4 lymphocytes or HTLV-1-infected MJ[G11] and HuT-102 lymphocytes were fragmented by sonication, and oligonucleosomal-protein complexes were precipitated using antibodies against candidate Myc-binding factors. Cross-links were reversed, and specific oligonucleotide DNA primer pairs were used in PCRs to amplify immunoprecipitated DNA regions spanning conserved E-box elements (PRM) or an untranslated sequence (UTR) as negative control (79) . Results in Fig. 5A (top panels) demonstrate that HTLV-1 p30
II was detected only bound to E-box enhancer elements in HTLV-1-infected lymphocytes. Myc, TRRAP, TIP49 (RUVBL1), TIP48 (RUVBL2), and the acetyltransferase hGCN5 (42) were present in chromatin-remodeling complexes in uninfected Molt-4 cells and in HTLV-1-infected MJ[G11] and HuT-102 lymphocytes (Fig. 5A, top  panels) . Surprisingly, TIP60 was detected only in Myc-containing transcription complexes that contained p30 II in HTLV-1-infected T cells (Fig. 5A, top panels) , consistent with coimmunoprecipitation results and observed effects of ectopic TIP60 in transactivation assays (see Fig. 2B and 4A) . The diminished recruitment of TIP49 to Myc-containing transcription complexes on the cyclin D2 promoter in HTLV-1-infected MJ[G11] cells was not attributable to apparent differences in p30 II /Myc/TIP60 interactions (Fig. 5A) . Histone H3 acetylation surrounding the E-box enhancer elements within the human cyclin D2 promoter, consistent with transcriptional activation, was detected in all cell types with the exception of H3, which appeared to be differentially acetylated on Lys-9 and Lys-14 residues in HTLV-1-infected MJ[G11] and HuT-102 cells, respectively (Fig. 5A, lower panels) . Differences in histone H3 acetylation, however, did not correlate with the stabilization of p30 II /Myc/TIP60 transcriptional interactions in HTLV-1-infected T-cell lines.
To identify residues within HTLV-1 p30 II that interact with Myc/TIP60 complexes in vivo, we generated a panel of pGEX 4T.1-glutathione S-transferase (GST)-HTLV-1 p30 II constructs, expressing full-length GST-HTLV-1 p30 II or various truncation mutants, GST-p30 II (residues 1 to 98), GST-p30 II (residues 99 to 154), GST-p30 II (residues 155 to 241) spanning the entire coding region of HTLV-1 p30 II (Fig. 5B , see diagram). These proteins were expressed in Escherichia coli BL21 bacteria, and purified recombinant GST-HTLV-1 p30 II fusion proteins were used in GST pull-down experiments as described by Harrod et al. (23) . GST proteins were incubated with HeLa nuclear extracts at 4°C overnight, and complexes were precipitated with glutathione-Sepharose 4B (Amersham-Pharmacia Biotech). The matrices were washed, and bound factors were eluted using 10 mM reduced glutathione buffer. Input levels of purified recombinant GST or GST-HTLV-1 p30 II proteins, Myc, and TIP60 are shown in Fig. 5B . Results shown in Fig. 5B (right panels) demonstrate that full-length GST-HTLV-1 p30 II interacts with both Myc and TIP60 in HeLa nuclear extracts. Deletion of amino acid residues from either the NH 2 terminus or COOH terminus of p30 II disrupts Myc binding; however, the TIP60-interacting region of HTLV-1 p30
II was mapped to residues between positions 99 and 154 (Fig. 5B ). Our future efforts will biochemically characterize specific amino acid contacts responsible for the stabilization of HTLV-1 p30 II /Myc/ TIP60 transcriptional interactions.
We next examined recruitment of HTLV-1 p30 II /Myc/TIP60 chromatin remodeling complexes to conserved, Myc-responsive E-box enhancer elements within the cyclin D2 promoter in cultured HTLV-1-infected ATLL patient lymphocytes (ATL-1). Chromatin-immunoprecipitations were performed using antibodies that recognize endogenous HTLV-1 p30 II (34), Myc, and known Myc-interacting factors as described previously. Polymerase chain-reaction amplification of ChIP products was performed using the PRM and UTR oligonucleotide DNA primer pairs (79) . Results shown in Fig. 5C demonstrate that p30 II is present in Myc/TIP60 transcription complexes assembled on E-box enhancer elements within the cyclin D2 promoter in HTLV-1 ATLL patient lymphocytes. The transcriptional coactivators, TRRAP/p434, TIP48, TIP49, and hGCN5 were also detected in p30 II /Myc/TIP60/cyclin D2 promoter complexes (Fig. 5C) .
HTLV-1 p30 II -GFP stabilizes Myc/TIP60 interactions and transactivates the cyclin D2 promoter in a TIP60 HAT-dependent manner. We next investigated whether HTLV-1 p30 II (HA) (48) . We therefore cotransfected 293A cells with CMV-HTLV-1 p30 II -GFP (kindly provided by G. Franchini, NCI, NIH [48] ) or a pcDNA3.1-GFP vector control and performed ChIP analyses. Nucleoprotein complexes were cross-linked by treatment with formaldehyde, and oligonucleosomal fragments were generated by brief sonication of extracted genomic DNA. Chromatin immunoprecipitations were performed as described above, and ChIP products were amplified by PCR using the PRM and UTR oligonucleotide DNA primer pairs (79) . Similar expression of
HTLV-1 p30
II -GFP and GFP proteins was visualized with transfected 293A fibroblasts by fluorescence microscopy ( Fig.  6A and B) . The HTLV-1 p30 II -GFP protein was immunoprecipitated and bound to Myc-containing transcription complexes on conserved E-box elements within the cyclin D2 promoter in transfected 293A fibroblasts, using an anti-GFP antibody (Fig. 6A) . No ChIP product was detected for the anti-GFP immunoprecipitation in 293A cells transfected with the pcDNA3.1-GFP control (Fig. 6B) . While the transcriptional coactivators TRRAP/p434, TIP48, TIP49, and hGCN5 were present in Myc-containing complexes in both HTLV-1 p30 II -GFP and GFP-expressing cells, the TIP60 HAT was detected predominantly in HTLV-1 p30 II -GFP/Myc/TIP60 complexes (compare Fig. 6A and B) . However, TIP60 was weakly present in Myc-containing ChIP complexes in GFP-expressing cells, consistent with the demonstration of pre-existing Myc-TIP60 interactions by Frank et al. (16) and Patel et al. (56) (Fig. 6B) .
FIG. 5. HTLV-1 p30
II is present in Myc-TIP60-containing chromatin-remodeling complexes in HTLV-1-infected lymphocytes. (A) Chromatin immunoprecipitation assays were performed with uninfected Molt-4 lymphocytes or HTLV-1-infected MJ[G11] and HuT-102 lymphocytes using antibodies that recognize various Myc-interacting factors (TIP60, TRRAP, TIP48, TIP49, and hGCN5; top panels) or acetylated forms of histone H3 (acetyl-K9 and acetyl-K14; lower panels). The PRM primer pair anneals to sequences flanking the conserved E-box elements within the human cyclin D2 promoter, and the UTR negative control primers anneal within an untranslated region (79) 
. (B) Purified recombinant GST-HTLV-1 p30
II or GST-p30 II (1 to 98), GST-p30 II (99 to 154), and GST-p30 II (155 to 241) truncated mutant proteins were incubated with HeLa nuclear extracts, and GST pull-down assays were performed as described previously (23) II -Myc/TIP60 transcription complexes recruited to Myc-responsive E-box elements within the genomic cyclin D2 promoter in cultured lymphocytes from an HTLV-1-infected ATLL patient (ATL-1). Chromatin immunoprecipitations were performed as for panel A, and PCR analyses of ChIP products were carried out using PRM and UTR oligonucleotide primer pairs (79 To determine whether the HTLV-1 p30 II -GFP protein also transcriptionally activates the human cyclin D2 promoter in a TIP60-dependent manner, we cotransfected 293A fibroblasts with a tk promoter-Renilla luciferase plasmid, a human cyclin D2 promoter-luciferase reporter plasmid, and CMV-HTLV-1 p30 II -GFP in the presence of increasing amounts of either CMV-TIP60 (wild-type) or CMV-TIP60 ⌬HAT , which expresses a trans-dominant-negative TIP60 mutant (7, 25, 48) . Results shown in Fig. 6C demonstrate that HTLV-1 p30 II -GFP transcriptionally activates the human cyclin D2 promoter approximately 14-fold in transfected 293A fibroblasts compared to an empty pcDNA3.1-GFP control. Overexpression of wild-type TIP60, in the presence of HTLV-1 p30 II -GFP, significantly increased p30
II -GFP-dependent transcriptional activity in a dose-dependent manner (Fig. 6C) . Coexpression of the transdominant-negative TIP60 ⌬HAT mutant (25) repressed p30 II -GFP-dependent transactivation from the human cyclin D2 promoter (Fig. 6C) , consistent with the results shown in Fig.  4A and with an essential role for the TIP60 HAT in HTLV-1 p30 II transcriptional activation. Relative Renilla luciferase activities for each sample are shown in Fig. 6D for comparisons of similar transfection efficiencies.
HTLV-1 p30
II transcriptionally activates numerous cellular genes in a TIP60-dependent or TIP60-independent manner. To comprehensively identify cellular gene sequences whose expressions are altered by HTLV-1 p30 II -TIP60 transcriptional interactions, we cotransfected 293A fibroblasts with a C␤S empty vector control, CMV-HTLV-1 p30 II (HA), or CMV-HTLV-1 p30 II (HA) and TIP60 ⌬HAT , which expresses a transdominant-negative mutant that interferes with endogenous TIP60 functions (25) . Total cellular RNAs were extracted, and microarray gene expression analyses were performed using Affymetrix Human U133Plus 2.0 full-genomic chips. Transcriptional activation of cellular target genes is expressed as activation (n-fold) relative to the empty C␤S vector control, and the lower limit for transactivation was set at 2.5-fold. Figure 7A shows a graphical representation of cellular target genes transcriptionally activated by HTLV-1 p30 II (HA) (red lines). TIP60-dependent gene sequences were identified based upon their transcriptional repression in the presence of the TIP60 ⌬HAT mutant (25) and are indicated by green lines (Fig.  7A) . In general, the fold transactivation by HTLV-1 p30 II (HA) ranged between 2.5-fold to 393-fold for specific target genes (Fig. 7A) . Michael (Fig. 7B) .
In Fig. 7C , we provide a representative list of the major target gene sequences that are transcriptionally activated by HTLV-1 p30 II (HA) as determined by Affymetrix microarray gene expression analyses. TIP60-dependent gene sequences are shown in boxes. Transcriptional activation is expressed as activation (n-fold) relative to the empty C␤S vector control. Numerous cellular genes were transcriptionally induced by HTLV-1 p30 II (HA) in a TIP60-dependent or TIP60-independent manner, suggesting that p30 II may participate in multiple, distinct transcription complexes (Fig. 7C) . With respect to the potential role of HTLV-1 p30 II in adult T-cell leukemogenesis, transcriptional activation of the following genes is of significant interest: myeloid cell nuclear differentiation 1 antigen (31.1-fold; TIP60 dependent), protocadherin 15 (26.1-fold; TIP60 dependent), human protein tyrosine phosphatase delta precursor (23.3-fold; TIP60 dependent), cadherin 11-like precursor (20.2-fold; TIP60 dependent), colony-stimulating factor 2 receptor beta (19.6-fold; TIP60 independent), human protein tyrosine phosphatase receptor type Z polypeptide (16.4-fold; TIP60 dependent), Schizosaccharomyces pombe RAD21-like protein (16-fold; TIP60 independent), human transmembrane phosphatase with tensin homology (15.5-fold; TIP60 independent), H2B histone family member N (15.1-fold; TIP60 independent), major histocompatibility complex class II DR beta 3 (14.0-fold; TIP60 dependent), human CD84 leukocyte antigen (14.0-fold; TIP60 independent), prostate-specific G proteincoupled receptor (14.0-fold; TIP60 independent), fibroblast growth factor 20 (13.8-fold; TIP60 dependent), protein kinase C alpha-binding protein (13.2-fold; TIP60 independent), regulator of G-protein-signaling 1 (13.1-fold; TIP60 dependent), cytoplasmic linker associated protein 2 (13.0-fold; TIP60 independent), POU domain 4 transcription factor 2 (12.8-fold; TIP60 independent), RNA-binding motif protein (RBMY2B) (12.6-fold; TIP60 independent). Robek et al. (62) have demonstrated that an infectious HTLV-1 molecular clone, ACH.p30 II , exhibits an approximately 20 to 50% reduction in transformation efficiency compared to the wild-type ACH.wt (62) , suggesting that p30 II is required for the full transforming potential of HTLV-1. Our microarray analyses indicate that numerous cellular genes are transcriptionally activated by p30 II , and proteins encoded by these genes may contribute to HTLV-1 leukemic transformation and development of ATLL.
HTLV-1 p30 II enhances Myc transforming potential and requires the TIP60 HAT and TRRAP/p434. As the c-Myc oncogene is known to cause cellular transformation (7, 41, 51), we next investigated whether HTLV-1 p30 II might influence Myc-associated transforming activity in focus formation assays using immortalized human WRN Ϫ/Ϫ fibroblasts, which lack Werner's syndrome helicase functions (45) . This cellular background was chosen because ATLL is an aging-related malignancy requiring clinical latency periods of 25 to 40 years prior to disease onset (29) , which suggests that genetic mutations linked to the aging process likely contribute to leukemogenesis. Werner's syndrome is a premature aging disorder (45) that mimics or recapitulates many of the clinical and cellular features of normal aging, and WRN locus (8p11-12) mutations have been found in HTLV-1-infected ATLL patient lymphocytes and in HTLV-1-infected mycosis fungoides/Sezary syndrome cells (4, 30, 53, 69, 82) . Neither c-Myc nor HTLV-1 p30 II (HA) alone significantly induces focus formation in immortalized human WRN Ϫ/Ϫ fibroblasts (Fig. 8A) . Surprisingly, in combination, HTLV-1 p30 II (HA)-Myc coexpression reproducibly induces between 35 and 58 foci in different assays (Fig.  8A and B) . The expression of HTLV-1 p30 II (HA) and c-Myc (FLAG) was detected in transformed colonies by immunofluorescence microscopy ( Fig. 8D and E) , and the p30 II protein appeared to be distributed throughout the nucleoplasm (Fig.  8C) . We also observed a high incidence of multinucleated giant cells in isolated HTLV-1 p30 II (HA) Myc-transformed fibroblasts that were expanded in culture, consistent with HTLV-1 p30 II -induced polyploidy observed during BrdU-FACS analyses ( Fig. 8F ; compare to control cells in Fig. 8D ). The expression of HTLV-1 p30 II (HA) in transformed fibroblasts was confirmed by immunoblotting using a monoclonal anti-HA antibody (Fig. 8E) . As expected, the majority of expanded HTLV-1 p30 II (HA)-expressing colonies showed increased levels of intracellular Myc protein by immunoblotting (Fig. 8F) . Indeed, these findings indicate that HTLV-1 p30
II markedly enhances the transforming potential of c-Myc and may promote genomic instability, resulting in polyploidy.
Our transcriptional activation data suggested that enhancement of Myc functions by HTLV-1 p30
II requires the coactivators TIP60 and TRRAP/p434. Therefore, we tested whether focus formation induced by coexpressing HTLV-1 p30 II (HA)-Myc might be affected by overexpressing wild-type TIP60 or TIP60 ⌬HAT and TIP60 L497A mutant proteins (17, 25) . Results from two independent experiments in Fig. 9A indicate that none of the TIP60 expression constructs, either alone or in combination with c-Myc, significantly induces focus formation in immortalized human WRN Ϫ/Ϫ fibroblasts. However, ectopic TIP60 markedly increases focus formation induced by HTLV-1 p30 II (HA)-Myc coexpression (Fig. 9A) . The trans-dominantnegative TIP60 ⌬HAT mutant completely abrogated colony formation by HTLV-1 p30 II (HA)-Myc, and the TIP60 L497A mutant partially inhibited focus formation (Fig. 9A) . Increased colony formation by HTLV-1 p30 II (HA)/Myc/TIP60, compared to inhibition of focus formation by the trans-dominantnegative TIP60 ⌬HAT mutant, is shown in Fig. 9B . Inhibition of TRRAP/p434, as a result of coexpressing increasing amounts of TRRAP antisense RNA (41), also significantly decreased focus formation by HTLV-1 p30 II (HA)-Myc (Fig. 9C) . These findings collectively agree with our transcriptional activation data and suggest that HTLV-1 p30 II enhances Myc transcriptional and transforming activities in a TIP60 HAT-and TRRAPdependent manner.
As we have mapped the TIP60-interacting domain of HTLV-1 p30 II to amino acid residues 99 to 154 through biochemical GST pull-down experiments (see Fig. 5B ), we next analyzed a naturally occurring truncation mutant of p30 II , HTLV-1 p13 II , which expresses the carboxyl terminus of p30 II , spanning from residue 155 to 241 (Fig. 10A) (1, 10, 34 (Fig. 10B) . We then analyzed BrdU incorporation and S-phase cell cycle progression in HTLV-1 p30 II (HA)-or p13 II (HA)-expressing transfected lymphoid cultures, compared to the C␤S control. Results shown in Fig. 10C demonstrate that p30 II (HA) expression markedly increased S-phase progression and polyploidy as noted in previous experiments (see Fig. 1D ), whereas neither p13 II (HA) nor the C␤S control resulted in altered cell cycle progression (Fig. 10C) .
To determine whether the TIP60-interacting domain (residues 99 to 154) of HTLV-1 p30 II (HA) is essential for its oncogenic function, we compared the ability of p30 II (HA) and p13 II (HA) (corresponding to amino acids 155 to 241 of HTLV-1 p30 II ) to promote focus formation in immortalized human WRN Ϫ/Ϫ fibroblasts in combination with c-Myc, as shown in Fig. 8A . These results demonstrate that the p13 II (HA) mutant, lacking residues 1 to 154 of p30 II , is significantly defective for cellular transformation and focus formation compared to wild-type p30 II (HA) (Fig. 10D) , suggesting that TIP60 recruitment is required for p30 II -associated oncogenic activity. Finally, we tested the capacity of HTLV-1 p30 II (HA) and p13 II (HA) to transcriptionally activate the human cyclin D2 promoter-luciferase reporter construct in transfected 293A fibroblasts. Results shown in Fig. 10E demonstrate that p13 II (HA), lacking the TIP60-interacting domain, is impaired for transcriptional-activating functions compared to p30 II (HA), which transactivates the cyclin D2 promoter approximately eight-to ninefold. Indeed, p13 II (HA) exhibited a trans-dominant-negative effect upon Myc-dependent transactivation from the cyclin D2 promoter and slightly repressed transcription below the basal level (Fig. 10E) . Chromatin-immunoprecipitation analyses were performed with 293A fibroblasts expressing either HTLV-1 p30 II (HA) or p13 II (HA), by using antibodies against HTLV-1 p30 II (the anti-HTLV-1 p30 II or TofII antibody recognizes a peptide epitope within the COOH terminus of p30 II that is also present in HTLV-1 p13 II [32] ), Myc, TIP60, TRRAP, TIP48, TIP49, and hGCN5. Immunoprecipitation products were amplified using the PRM primer pair, which anneals to nucleotide sequences flanking the conserved Myc-responsive E-box elements within the human cyclin D2 gene promoter (79) . The p30 II (HA) protein was precipitated in Myc-containing chromatin-remodeling complexes that contain TIP60, TRRAP, TIP48, TIP49, and hGCN5 (Fig.  10F, top panel) . However, the p13 II (HA) protein was not detected bound to Myc-responsive E-box elements within the cyclin D2 promoter and, consistent with p13 II 's transcriptional impairment, the TIP60 HAT was not present in Myc-containing cyclin D2 promoter complexes in the absence of p30 II (HA) (Fig. 10F, lower panel) . Our data suggest that the HTLV-1 p30 II oncoprotein enhances Myc-dependent transcriptional and transforming activities through the stabilization of Myc-TIP60 interactions on promoters of Myc-responsive genes, which may also influence the acetylation of Myc protein by the TIP60 coactivator (Fig. 11) (56) .
DISCUSSION
HTLV-1 infects CD4
ϩ T cells and promotes deregulated cell growth and lymphoproliferation associated with the development of ATLL. While numerous studies have demonstrated that the viral Tax protein transcriptionally activates growth/ proliferative-signaling pathways, it has become increasingly evident that other pX-encoded regulatory factors (p12  I , p13  II ,  p30 II , Rex) are likely to perform essential functions during adult T-cell leukemogenesis (1, 6, 29, 34, 35, 48, 85) . Indeed, the majority of partially deleted HTLV-1 proviruses in ATLL patient isolates contain intact pX sequences (33, 68) , and alternatively spliced ORF I and ORF II mRNAs in HTLV-1-infected transformed T-cell lines and ATLL patient samples have been detected (6, 35) . Cytotoxic T-lymphocytes specifically targeted against ORF I and ORF II peptides have been obtained from ATLL patients, suggesting that these proteins are present during in vivo HTLV-1 infections (57). Zhang et al. (86) reported that p30 II interacts with p300/CREB-binding protein and represses Tax-mediated transactivation from the HTLV-1 LTR (86) and differentially modulates CREB-dependent transcription (87 (1, 10, 34, 70) . The TIP60-interacting region is located between amino acid residues 99 and 154, and the nuclear localization sequence (NLS) is depicted as described in reference 1. The transcriptional activating domain of HTLV-1 p30 II has been previously mapped to residues 62 to 220 (1, 86, 87) , which spans a region bearing significant amino acid sequence similarities to homeotic transcription factors, including Oct1, Pit1, and POU (1, 34) . II (this antibody recognizes a peptide epitope within the COOH terminus of p30 II and p13 II ) (34), Myc, TIP60, TRRAP, TIP48, TIP49, and hGCN5. Precipitated oligonucleosomal DNA fragments, spanning conserved Myc-responsive E-box enhancer elements within the human cyclin D2 promoter, were amplified by PCR using the PRM oligonucleotide primer pair (79 II markedly enhances Myc-associated transcriptional and transforming activities and increases S-phase progression and polyploidy through interactions with the coactivator/HAT, TIP60 (Fig. 11) . HTLV-1 p30 II transactivates conserved E-box enhancer elements within promoters of Myc-responsive genes, requiring TIP60 HAT activity and the transcriptional coactivator TRRAP/p434. Frank et al. (16) have shown that preexisting Myc-TIP60 interactions contribute to Myc-dependent transcriptional activation and chromatin-remodeling associated with histone H4 acetylation on a subset of Myc-responsive genes in rodent and human fibroblasts, although their data suggest that Myc-TIP60 interactions may be relatively unstable on certain promoters. Patel et al. also recently demonstrated that c-Myc is a substrate for lysine acetylation by the TIP60 and hGCN5 acetyltransferases (56) . Indeed, Myc and the TIP60 HAT likely exist in multiple distinct nuclear complexes, and Park et al. have demonstrated that TIP60 is not present in Myc/BAF53-containing transcription complexes (54) . Our data indicate that, in absence of HTLV-1 p30 II -interactions, ectopic TIP60 overexpression does not significantly alter Myc transcriptional and transforming activities in functional assays (see Fig. 4A , 6C, and 9A). Further, we have shown that TIP60 is not detectably present in Myc-containing chromatin-remodeling complexes on the human cyclin D2 promoter (7, 79) , in the absence of HTLV-1 p30 II , in uninfected Molt-4 lymphocytes (Fig. 5A) . However, we did detect weak recruitment of TIP60 to Myc transcription complexes on the cyclin D2 promoter in pcDNA3.1-GFP-transfected 293A fibroblasts by ChIPs (Fig.   6B ), consistent with the notion that Myc-TIP60 interactions may be relatively unstable on certain gene promoters. Thus, aberrant stabilization of Myc-TIP60 interactions, as a result of HTLV-1 p30 II or other stabilizing factors, may contribute prominently to neoplastic transformation in hematological malignancies and solid tumors where Myc functions are deregulated or where myc locus mutations are present (18, 24, 26, 43, 55, 60) .
The GST-HTLV-1 p30 II protein interacts with both Myc and TIP60, and amino acid residues located between positions 99 and 154 of p30 II interact with the TIP60 HAT in vivo. Recruitment of TIP60 is essential for p30 II -dependent effects upon cell cycle progression and focus formation/transformation. Affymetrix microarray gene expression analyses indicate that numerous cellular genes are transcriptionally activated by HTLV-1 p30 II in a TIP60-dependent or TIP60-independent manner. These gene products could play important roles in HTLV-1-associated neoplastic disease. Our results indicate that HTLV-1 p30 II is a novel retroviral enhancer of Myc-TIP60 transcriptional and transforming activities that may contribute to adult T-cell leukemogenesis.
